African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients

Pharmacotherapy

Volumn 35, Issue 6, 2015, Pages 569-577

  Taber, David J ^a,b   Gebregziabher, Mulugeta G ^a   Srinivas, Titte R ^a   Chavin, Kenneth D ^a   Baliga, Prabhakar K ^a   Egede, Leonard E ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

acute rejection; African American; kidney transplantation; tacrolimus; therapeutic drug monitoring

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; ANTIBODY MEDIATED REJECTION; ARTICLE; ATROPHY; BK VIRUS INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; MORTALITY; RACE DIFFERENCE; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; TUBULAR ATROPHY; CHEMICALLY INDUCED; DOSE RESPONSE; ETHNOLOGY; FIBROSIS; GRAFT REJECTION; KIDNEY TUBULE; MIDDLE AGED; PATHOLOGY;

ADULT; AFRICAN AMERICANS; ATROPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROSIS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TACROLIMUS;

EID: 84931955579     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1591     Document Type: Article

References (34)

1. Disease K,. Improving Global Outcomes (KDIGO) Transplant Work Group: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1-155.
2. Wallemacq P, Armstrong VW, Brunet M, et al., Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009; 31: 139-52.
3. Kuypers DR,. Immunosuppressive drug monitoring-what to use in clinical practice today to improve renal graft outcome. Transplant Int 2005; 18: 140-50.
4. Bouamar R, Shuker N, Hesselink DA, et al., Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials. Am J Transplant 2013; 13: 1253-61.
5. Borobia AM, Romero I, Jimenez C, et al., Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit 2009; 31: 436-42.
6. Undre N, Van Hooff J, Christiaans M, et al., Low systemic exposure to tacrolimus correlates with acute rejection. Transplantation 1999; 31: 296-8.
7. Richards KR, Hager D, Muth B, Astor BC, Kaufman D, Djamali A,. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. Transplantation 2014; 97: 986-91.
8. Malat GE, Culkin C, Palya A, Ranganna K, Kumar MS,. African American kidney transplantation survival: the ability of immunosuppression to balance the inherent pre- and post-transplant risk factors. Drugs 2009; 69: 2045-62.
9. Neylan JF,. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 kidney transplant study group. Transplantation 1998; 65: 515-23.
10. Padiyar A, Augustine JJ, Bodziak KA, Aeder M, Schulak JA, Hricik DF,. Influence of African-American ethnicity on acute rejection after early steroid withdrawal in primary kidney transplant recipients. Transplant Proc 2010; 42: 1643-7.
11. Mancinelli LM, Frassetto L, Floren LC, et al., The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24-31.
12. Vadivel N, Garg A, Holt DW, Chang RW, MacPhee IA,. Tacrolimus dose in black renal transplant recipients. Transplantation 2007; 83: 997-9.
13. MacPhee IA, Holt DW,. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation 2008; 85: 163-5.
14. Higgins R, Fishman J,. Disparities in solid organ transplantation for ethnic minorities: facts and solutions. Am J Transplant 2006; 6: 2556-62.
15. Yasuda S, Zhang L, Huang S,. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84: 417-23.
16. Staatz C, Taylor P, Tett S,. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 2001; 16: 1905-9.
17. Bottiger Y, Brattstrom C, Tyden G, Sawe J, Groth CG,. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 1999; 48: 445-8.
18. Kershner RP, Fitzsimmons WE,. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920-6.
19. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ,. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States multicenter FK506 kidney transplant group. Transplantation 1996; 62: 900-5.
20. Naesens M, Lerut E, Damme B, Vanrenterghem Y, Kuypers DR,. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant 2007; 7: 2114-23.
21. Haufroid V, Wallemacq P, Van Kerckhove V, et al., CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 2006; 6: 2706-13.
22. Hesselink DA, van Schaik RH, van der Heiden I.P., et al., Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54.
23. Leffell MS, Steinberg AG, Bias WB, Machan CH, Zachary AA,. The distribution of HLA antigens and phenotypes among donors and patients in the UNOS registry. Transplantation 1994; 58: 1119.
24. Rebellato LM, Arnold AN, Bozik KM, Haisch CE,. HLA matching and the United Network for Organ Sharing Allocation System: impact of HLA matching on African-American recipients of cadaveric kidney transplants. Transplantation 2002; 74: 1634.
25. Matas A, Smith J, Skeans M, et al., OPTN/SRTR 2011 annual data report: kidney. Am J Transplant 2012; 13: 11-46.
26. McDaniel D, Barber W, Nguyan C, et al., Combined analysis of cytokine genotype polymorphism and the level of expression with allograft function in African-American renal transplant patients. Transpl Immunol 2003; 11: 107-19.
27. Hutchings A, Purcell WM, Benfield MR,. Increased costimulatory responses in African-American kidney allograft recipients. Transplantation 2001; 71: 692-5.
28. Kerman RH, Kimball P, Van Buren CT, Lewis RM, Kahan BD,. Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation 1991; 51: 338.
29. de Mattos AM, Olyaei AJ, Bennett WM,. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-46.
30. Lo A, Egidi MF, Gaber LW, et al., Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. Clin Transplant 2004; 18: 53-61.
31. Shapiro R, Vivas C, Scantlebury VP, et al., "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. Transplantation 1996; 62: 1242-6.
32. Hesselink DA, Bouamar R, Elens L, van Schaik RHN, van Gelder T,. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet 2014; 53: 123-39.
33. Hricik DE, Knauss TC, Bodziak KA, et al., Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003; 76: 938-42.
34. Patel N, Taber DJ, Weimert NA, et al., Potential differences in kidney allograft outcomes between ethnicities when converting to sirolimus base immunosuppression. Transplant Proc 2009; 41: 4131-7.